Table 2.
Proportions of patients found to have a ‘Response to Treatment’ with MultiCruzi using a threshold of −0.7 and with PCR per treatment group
| Dosing regimen | Total Number of patients | Patients with “Response to Treatment” | Patients with PCR “Parasitological Clearance” |
|---|---|---|---|
| BZN—150 mg for 4 Weeks | 30 | 15 (50.00%) | 24 (80.00%) |
| BZN—300 mg for 2 Weeks | 29 | 12 (41.38%) | 23 (79.31%) |
| BZN—300 mg for 4 Weeks | 28 | 13 (46.43%) | 25 (89.29%) |
| BZN—300 mg for 8 Weeks | 28 | 16 (57.14%) | 24 (85.71%) |
| BZN—150 mg + E1224 for 4 Weeks | 27 | 12 (44.44%) | 23 (85.19%) |
| BZN—300 mg + E1224 for 8 Weeks | 29 | 16 (55.17%) | 24 (82.76%) |
| Placebo | 30 | 3 (10.00%) | 1 (3.33%) |
BZN Benznidazole; (1) BZN—150 mg for 4 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 4 weeks; (2) BZN—300 mg for 2 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 2 weeks; (3) BZN—300 mg for 4 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 4 weeks; (4) BZN—300 mg for 8 Weeks: samples collected from individuals treated with 300 mg of Benznidazole daily for 8 weeks; (5) BZN—150 mg + E1224 for 4 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 4 weeks plus fosravuconazole; (6) BZN—300 mg + E1224 for 8 Weeks: samples collected from individuals treated with 150 mg of Benznidazole daily for 8 weeks plus fosravuconazole and (7) Placebo: samples collected from individuals treated with Placebo. The proportions of patients were calculated at a log ratio threshold of the DF50 of −0.7.